Corcept Therapeutics (CORT) Misses Q1 EPS by 19c ; Offers Guidance
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $111.62 -1.05%
EPS Growth %: +393.8%
Financial Fact:
Basic and diluted net loss per share: 0.02
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +393.8%
Financial Fact:
Basic and diluted net loss per share: 0.02
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q1 EPS of ($0.30), $0.19 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $164.9 million versus the consensus estimate of $183.28 million.
GUIDANCE:
Corcept Therapeutics sees FY2026 revenue of $0.95-1.05 billion, versus the consensus of $0.93 billion.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
- UBS Upgrades E.ON SE (EOAN:GR) (EONGY) to Buy
- Bernstein SocGen Group Reiterates Outperform Rating on Zydus Lifesciences (ZYDUSLIF:IN)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
